推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

[HTML] from hematologylibrary.orgQ Jiang, LP Xu, DH Liu, KY Liu… - …, 2011 - bloodjournal.hematologylibrary.org
The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib
for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been
evaluated. This cohort study was designed to compare the outcomes of imatinib (n = 87) ...
Related articles - All 6 versions

Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia …

VS Nadarajan, CL Phan, CH Ang, KL Liang… - International journal of …, 2011 - Springer
Abstract The outcome of treating chronic myeloid leu- kemia (CML) with imatinib mesylate
(IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared
to early chronic phase. This may be attributed to additional genomic alterations that ...
Cited by 1 - Related articles - All 3 versions

Development of t (8; 21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple …

V Najfeld, N Wisch, J Mascarenhas, L Issa… - Cancer Genetics, 2011 - Elsevier
... Trisomy 8, double Ph, or other chromosomal abnormalities in lymphoid or myeloid cells are
detected in patients in accelerated phase or blast crisis CML, and specifically occur in
descendents of clonal Ph + cells, consistent with a stepwise process. ...
Related articles - All 3 versions

… newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd …

[HTML] from thelancet.comHM Kantarjian, A Hochhaus, G Saglio… - The Lancet …, 2011 - Elsevier
... 3 Significantly fewer patients on nilotinib progressed or transformed to accelerated phase or blast
phase than did patients on imatinib. 3 Here, we present updated results of the ENESTnd trial for
patients with a minimum of 24 months of follow-up. Methods. Patients. ...
Cited by 1

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

CA Eide, LT Adrian, JW Tyner, M Mac Partlin… - Cancer research, 2011 - AACR
... alone or with DCC-2036 (0.2–3,125 nmol/L) or imatinib (0.2–3,125 nmol/L) as described (8).
For primary cell experiments, following informed consent, peripheral blood mononuclear cells
from a newly diagnosed CML patient and from an accelerated phase patient harboring ...
Cited by 2 - Related articles - All 4 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451